Novartis oncology partnership with Antares, shares trade near analyst targets

Novartis enters a new cancer drug discovery collaboration with Antares Therapeutics while expanding disability access initiatives, as the Swiss blue-chip stock trades close to consensus price targets on SIX Swiss Exchange.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-27, 14:54.

Novartis (CH0012005267) is adding a fresh strategic layer to its oncology pipeline. The Swiss healthcare group, listed on SIX Swiss Exchange, has agreed a new cancer research partnership with Antares Therapeutics targeting historically undruggable tumor pathways, according to a recent Simply Wall St analysis.Simply Wall St report on the Novartis Antares partnership

New push in cancer R&D

The Antares collaboration focuses on small molecule drug candidates for cancer targets that have so far resisted conventional pharmaceutical approaches, broadening Novartis' oncology research footprint beyond its established franchises.Simply Wall St report on undruggable cancer targets The arrangement adds to the company's existing cancer pipeline, where Pluvicto is cited as a multi-billion-dollar opportunity in recent market commentary.Finanzen100 overview mentioning Pluvicto growth potential

Beyond laboratory research, Novartis is also deepening patient-focused initiatives. The company has announced a collaboration with accessibility platform Becoming rentABLE to support more inclusive travel options for people living with spinal muscular atrophy, strengthening its broader patient impact agenda alongside drug development efforts.Simply Wall St coverage of the disability access initiative

How the stock looks to analysts

For investors, Novartis shares trade at CHF126.28 on SIX Swiss Exchange, with the stock up 35.3 percent over the past twelve months and 63.9 percent over three years, according to Simply Wall St.Simply Wall St performance figures for Novartis The same analysis cites a consensus analyst price target of CHF125.03, implying the current level sits around 1 percent above that benchmark.

On a valuation basis, Simply Wall St flags Novartis as trading roughly 59.3 percent below its estimated intrinsic value, a metric based on discounted cash flow assumptions.Simply Wall St valuation snapshot for Novartis Separate data for the New York-listed Novartis American Depositary Receipts shows the NVS ticker closing at 155.30 US dollars on Nasdaq on June 26, with a market capitalization around 296.33 billion US dollars and a trailing price-earnings ratio of 22.10.TradingKey quote page for Novartis NVS ADR

The products behind Novartis

Novartis generates most of its revenue from branded prescription medicines across oncology, immunology, neuroscience and cardiovascular disease. Pluvicto, its radioligand therapy for metastatic castration-resistant prostate cancer, has been highlighted in recent commentary as a multi-billion-dollar growth driver, reflecting the company's focus on targeted therapies with strong clinical data.Finanzen100 mention of Pluvicto opportunity at Novartis

Where the Novartis shares trade today

The Novartis shares (CH0012005267) trade on SIX Swiss Exchange at CHF126.28 as of 2026-06-26, based on Simply Wall St figures, with the New York ADRs (ticker NVS) quoted at 155.30 US dollars on Nasdaq at the June 26 close.Simply Wall St quote snapshot for Novartis on SIXTradingKey closing price data for Novartis NVS ADR

Key data on the Novartis shares

• Company: Novartis AG
• ISIN: CH0012005267
• WKN: 904278
• Ticker: NOVN (SIX), NVS (Nasdaq ADR)
• Trading venue: SIX Swiss Exchange, Nasdaq (ADR)
• Price (as of 2026-06-26, 16:00): 126.28 CHF (SIX), 155.30 USD (Nasdaq ADR)
• Market cap: 296.33 billion USD (as of 2026-06-26)
• Sector / industry: Health Care, Pharmaceuticals
• Index membership: SMI, Stoxx Europe 50
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, tax advice, or a recommendation to buy or sell securities. All data are based on sources cited and may change without notice.